Search Page

1

Cite

Share

The enzymatic activity of inositol hexakisphosphate kinase controls circulating phosphate in mammals.

Moritoh Y, Abe SI, Akiyama H, Kobayashi A, Koyama R, Hara R, Kasai S, Watanabe M. Moritoh Y, et al. Nat Commun. 2021 Aug 11;12(1):4847. doi: 10.1038/s41467-021-24934-8. Nat Commun. 2021. PMID: 34381031 Free PMC article.

Cite

Share

2

Cite

Share

Transcarotid balloon aortic valvuloplasty for critical aortic stenosis in an infant weighing 890 g.

Nakagawa N, Kamada M, Moritoh Y. Nakagawa N, et al. Among authors: moritoh y. Cardiol Young. 2021 Feb;31(2):294-296. doi: 10.1017/S1047951120003558. Epub 2020 Nov 16. Cardiol Young. 2021. PMID: 33196406

Cite

Share

3

Cite

Share

Enteropeptidase inhibition improves kidney function in a rat model of diabetic kidney disease.

Sugama J, Katayama Y, Moritoh Y, Watanabe M. Sugama J, et al. Among authors: moritoh y. Diabetes Obes Metab. 2021 Jan;23(1):86-96. doi: 10.1111/dom.14190. Epub 2020 Oct 6. Diabetes Obes Metab. 2021. PMID: 32893449 Free PMC article.

Cite

Share

4

Cite

Share

Discovery and characterization of a small-molecule enteropeptidase inhibitor, SCO-792.

Sasaki M, Miyahisa I, Itono S, Yashiro H, Hiyoshi H, Tsuchimori K, Hamagami KI, Moritoh Y, Watanabe M, Tohyama K, Sasaki M, Sakamoto JI, Kawamoto T. Sasaki M, et al. Among authors: moritoh y. Pharmacol Res Perspect. 2019 Sep 4;7(5):e00517. doi: 10.1002/prp2.517. eCollection 2019 Oct. Pharmacol Res Perspect. 2019. PMID: 31508234 Free PMC article.

Cite

Share

5

Cite

Share

Enteropeptidase inhibition improves obesity by modulating gut microbiota composition and enterobacterial metabolites in diet-induced obese mice.

Sugama J, Moritoh Y, Yashiro H, Tsuchimori K, Watanabe M. Sugama J, et al. Among authors: moritoh y. Pharmacol Res. 2021 Jan;163:105337. doi: 10.1016/j.phrs.2020.105337. Epub 2020 Dec 1. Pharmacol Res. 2021. PMID: 33276106 Free article.

Cite

Share

6

Cite

Share

Erratum. SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans. Diabetes 2021;70:2364-2376.

Nishizaki H, Matsuoka O, Kagawa T, Kobayashi A, Watanabe M, Moritoh Y. Nishizaki H, et al. Among authors: moritoh y. Diabetes. 2021 Oct 29:db22er01b. doi: 10.2337/db22-er01b. Online ahead of print. Diabetes. 2021. PMID: 34957484 No abstract available.

Cite

Share

7

Cite

Share

SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans.

Nishizaki H, Matsuoka O, Kagawa T, Kobayashi A, Watanabe M, Moritoh Y. Nishizaki H, et al. Among authors: moritoh y. Diabetes. 2021 Oct;70(10):2364-2376. doi: 10.2337/db21-0451. Epub 2021 Jul 28. Diabetes. 2021. PMID: 34321316 Free PMC article. Clinical Trial.

Cite

Share

8

Cite

Share

Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats.

Koyama R, Ookawara M, Watanabe M, Moritoh Y. Koyama R, et al. Among authors: moritoh y. Mol Pharmacol. 2021 Apr;99(4):286-293. doi: 10.1124/molpharm.120.000168. Epub 2021 Feb 5. Mol Pharmacol. 2021. PMID: 33547250

Cite

Share

9

Cite

Share

Enteropeptidase inhibitor SCO-792 effectively prevents kidney function decline and fibrosis in a rat model of chronic kidney disease.

Katayama Y, Sugama J, Suzuki T, Ishimura Y, Kobayashi A, Moritoh Y, Watanabe M. Katayama Y, et al. Among authors: moritoh y. Nephrol Dial Transplant. 2021 Mar 29;36(4):631-640. doi: 10.1093/ndt/gfaa349. Nephrol Dial Transplant. 2021. PMID: 33351150 Free PMC article.

Cite

Share

10

Cite

Share

Erratum. SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans. Diabetes 2021;70:2364-2376.

Nishizaki H, Matsuoka O, Kagawa T, Kobayashi A, Watanabe M, Moritoh Y. Nishizaki H, et al. Among authors: moritoh y. Diabetes. 2021 Oct 29:db22er01b. doi: 10.2337/db22-er01b. Online ahead of print. Diabetes. 2021. PMID: 34716201 No abstract available.

Cite

Share